Intergroup, Italian Melanoma. 2025. “30 | Sonidegib for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome and EADO Stage IIb Sporadic Basal Cell Carcinomas: A Phase II Study (SIBLINGS trial): Sara Farinatti1|2, Giuseppe Agenziano3, Emi Dika4|5, Emanuela Passoni6, Ketty Peris7, Pietro Quaglino8, Paola Queirolo9, Massimiliano Scalvenzi10, Iris Zalaudek11, Luigi Lorini11, Cristina Gurizzan1, Monica Variolo1|2, Paolo Bossi*1|2, Carlo Resteghini*1|2 | 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; 2Department of Biomedical Sciences, Humanitas University, Rozzano MI; 3Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 4Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna; 5Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; 6Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Dermatologic Clinic, University of Turin Medical School, Turin; 9Medical Oncology Unit; 10Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; 11Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed Equally”. Dermatology Reports, December. https://doi.org/10.4081/dr.2025.10772.